STOCKHOLM, SWEDEN - January 21, 2026. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has signed a binding term sheet with Exeltis, a global Women ...

Karolinska Development AB ( (SE:KDEV)) has issued an announcement. Karolinska Development’s portfolio company, SVF Vaccines, has presented promising preclinical data on its immunotherapy, SVF-001, ...

STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in the phase 2a ...

(RTTNews) - Karolinska Development AB (KDEV.ST) on Monday announced plans to raise around SEK 202.6 million through a rights issue of class B shares, pending approval at an Extraordinary General ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

STOCKHOLM - 14 November 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-September 2025. The full report is available on the Company's website. "We ...

STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in the phase 2a ...

(MENAFN- GlobeNewsWire - Nasdaq) STOCKHOLM, SWEDEN – October 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has been granted a patent in ...

STOCKHOLM, SWEDEN - October 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has been granted a patent in the US protecting its drug ...

STOCKHOLM, SWEDEN – July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the portfolio company Umecrine Cognition has raised SEK 24.6 million through a convertible ...